Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Squalamine for Retinal Neovascularization in PDR
NCT01769183Phase 2Completed
- Sponsor
- Elman Retina Group
- Start
- Feb 2013
- Primary completion
- Aug 2014
- Modality
- Multivalent & Scaffold-Based Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of squalamine in Retinal neovascularization, sponsored by Elman Retina Group. Started Feb 2013; status: completed.
02
Drugs
squalamine
03
Conditions
Retinal neovascularization
Beyond the preview
Go deeper on NCT01769183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01769183.